SYNCHRONIZE-1: Survodutide once weekly for adults with obesity
At week 76, mean body-weight change was -12.2% with 3.6 mg and -13.0% with 6.0 mg versus -5.4% with placebo; 72.6%, 71.9% and 46.3%, respectively, achieved at least 5% weight reduction.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity, or overweight with an obesity complication, without diabetes
n=725
At week 76, mean body-weight change was -12.2% with 3.6 mg and -13.0% with 6.0 mg versus -5.4% with placebo; 72.6%, 71.9% and 46.3%, respectively, achieved at least 5% weight reduction.
The trial excluded diabetes and lasted 76 weeks; longer-term outcomes and broader population generalisability remain to be established.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
At week 76, mean body-weight change was -12.2% with 3.6 mg and -13.0% with 6.0 mg versus -5.4% with placebo; 72.6%, 71.9% and 46.3%, respectively, achieved at least 5% weight reduction.